We bring you the latest news from the healthcare about the health care in the United Kingdom.

dinsdag 18 september 2018

The Lancet: [Comment] Informing NCD control efforts in India on the eve of Ayushman Bharat

[Comment] Informing NCD control efforts in India on the eve of Ayushman Bharat
The Government of India recently launched the ambitious National Health Protection Mission, also referred to as Ayushman Bharat (which means "bless India with long healthy life"), Pradhan Mantri Jan Arogya Yojana, or Modicare. This scheme has two main pillars: strengthening of universal comprehensive primary health care and a health insurance scheme to cover 500 million people in need to reduce catastrophic out-of-pocket health spending.1,2 The 1·3 billion population of India has vast socioeconomic and health diversity across the country.
Read more

[Comment] Offline: The new politics of health in India
"There is a full-blown crisis in India." So said Rahul Gandhi, President of the Indian National Congress Party, during a visit to the London School of Economics last month. He was talking about a "jobs crisis". But there is also a health crisis, as five papers published across three Lancet specialty journals—Lancet Oncology, Global Health, and Public Health—set out this week. Now is the right moment to be debating the future health of the world's largest democracy. In April, 2019, Indian voters will go to the polls in the most important general election since India achieved independence in 1947.
Read more

[Correspondence] Support for UNRWA's survival
The United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA) provides life-saving humanitarian aid for 5·4 million Palestine refugees now entering their eighth decade of statelessness and conflict. About a third of Palestine refugees still live in 58 recognised camps. UNRWA operates 702 schools and 144 health centres, some of which are affected by the ongoing humanitarian disasters in Syria and the Gaza Strip. It has dramatically reduced the prevalence of infectious diseases, mortality, and illiteracy.
Read more

[Comment] Treatment of bronchiectasis exacerbations in children: which antibiotic?
Bronchiectasis in children that is unrelated to cystic fibrosis is a relatively neglected disease. However, it is an important cause of respiratory morbidity in low-income and middle-income countries (occurring as a sequela of lower respiratory tract infection) as well as in specific populations in high-income countries such as Aboriginal or Maori and Pacific Islander populations.1 Most adult bronchiectasis has its roots in childhood disease, with up to 80% of adult patients reporting chronic symptoms from childhood.
Read more

[Articles] Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial
By 21 days of treatment, azithromycin is non-inferior to amoxicillin–clavulanate for resolving exacerbations in children with non-severe bronchiectasis. In some patients, such as those with penicillin hypersensitivity or those likely to have poor adherence, azithromycin provides another option for treating exacerbations, but must be balanced with risk of treatment failure (within a 20% margin), longer exacerbation duration, and the risk of inducing macrolide resistance.
Read more